Knapp J Z
Research & Development Associates, Incorporated, Somerset, N.J., USA.
PDA J Pharm Sci Technol. 1998 Jul-Aug;52(4):173-81.
Until the recent past, sterility of an injectable product was only discussed in absolute terms. Any description of sterility other than as an absolute could simply not be envisioned. While dealing in absolute yes/no statements is philosophically satisfying, these yes/no statements can't accommodate all real world scientific problems. Among these problems is the sterility problems faced in the mass production of injectable compounds. Many descriptions of procedures employed to achieve sterility in parenteral production batches were reported in the literature. The theoretical framework that could unite the widespread observations and practices into practical methodology was missing until recently. Production line control of the sterility of injectable products was essentially based on gut evaluations. The present achievement of rational, production line control of product sterility is based on the recognition that product sterility could not be simply regarded as a sharply edged yes/no affair. The present rational control is based on the fact that the sterility of a product is determined by the degree of contamination in the product prior to sterilization and to the parameters of the sterilization process. The end result of the sterilization process is now described as a probabalistic reduction of the initial contamination. The essential laboratory measurements on which this conclusion was based is due to Pflug (1-3). He assembled a theoretical framework, based on experimental data, that characterizes the sterility achieved in an injectable product with a single number. The end result of the sterilization process is now described as a probabalistic reduction of the initial contamination. As in many disciplines, the ability to achieve an objective evaluation of this important attribute provided the basis for scientific analysis, improved control and thus improved production and reduced cost. An equivalent framework is essential for the communication and standardization of the results of a visual inspection for contaminating particles. The control of particle contamination in injectable products is a two-fold problem for the pharmaceutical industry. The two parts of the problem are 1) achieving contamination free product and 2) achieving this contamination free quality at an economic cost acceptable to the user. Today, there is no commonly accepted framework for the definition or analysis of the results of a manual inspection for "visible" particles. Any progress toward global harmonization of the results of a visual particle inspection must commence with the development of a common scientific language with which inspection security and economic effectiveness of an inspection can be discussed and rationally evaluated. The tools with which to define and control the results of this inspection have been developed in biophysics, illumination engineering, optics, pharmaceutical manufacturing and statistics. With them, statistically replicable measures have been developed. The statistically replicable measures are then used to evaluate the results of semi- and fully automated particle inspection systems in terms of human inspection performance. The numerical evaluation of both the freedom from contamination achieved with an inspection for particle contamination and the economic effectiveness of the inspection are compared to Pflug's sterility index. In the case of particle contamination, the final product quality depends on product quality prior to inspection and to the parameters of the inspection process.
直到最近,注射用产品的无菌性还只是从绝对意义上进行讨论。除了绝对无菌之外,其他任何关于无菌性的描述根本无法想象。虽然处理绝对的是/否陈述在哲学上令人满意,但这些是/否陈述无法涵盖所有现实世界中的科学问题。其中一个问题就是注射用化合物大规模生产中面临的无菌性问题。文献中报道了许多用于实现肠胃外生产批次无菌性的程序描述。直到最近,将广泛的观察结果和实践统一为实用方法的理论框架一直缺失。注射用产品无菌性的生产线控制基本上基于主观判断。目前实现对产品无菌性进行合理的生产线控制,是基于认识到产品无菌性不能简单地被视为一个界限分明的是/否问题。目前的合理控制基于这样一个事实,即产品的无菌性取决于灭菌前产品中的污染程度以及灭菌过程的参数。现在将灭菌过程的最终结果描述为初始污染的概率性降低。得出这一结论所依据的重要实验室测量工作归功于普夫吕格(1 - 3)。他基于实验数据构建了一个理论框架,用一个单一数字来表征注射用产品所达到的无菌性。现在将灭菌过程的最终结果描述为初始污染的概率性降低。与许多学科一样,能够对这一重要属性进行客观评估为科学分析、改进控制提供了基础,从而提高了生产效率并降低了成本。对于目视检查污染颗粒结果的交流和标准化而言,一个等效的框架至关重要。注射用产品中颗粒污染的控制对制药行业来说是一个双重问题。这个问题的两个方面是:1)生产出无污染物的产品;2)以用户可接受的经济成本实现这种无污染质量。如今,对于“可见”颗粒的人工检查结果的定义或分析,尚无普遍接受的框架。在目视颗粒检查结果全球协调方面取得的任何进展,都必须从开发一种通用科学语言开始,借助这种语言可以讨论并合理评估检查的安全性和经济有效性。用于定义和控制这种检查结果的工具已在生物物理学、照明工程、光学、制药制造和统计学等领域得到开发。利用这些工具,已经开发出了具有统计可重复性的测量方法。然后,这些具有统计可重复性的测量方法被用于根据人工检查性能来评估半自动和全自动颗粒检查系统的结果。将颗粒污染检查所实现的无污染程度的数值评估以及检查的经济有效性与普夫吕格的无菌指数进行比较。就颗粒污染而言,最终产品质量取决于检查前的产品质量以及检查过程的参数。